Abstract
Although sunitinib shows a high response rate in patients with untreated metastatic renal cell carcinoma (mRCC), quite a few patients show no therapeutic effect. Therefore, it is crucial to distinguish the patients who respond to sunitinib from those who do not as early as possible after the administration of the therapy. We herein report a case of mRCC in which 11C-acetate (AC) positron emission tomography (PET) showed an early therapeutic effect of sunitinib treatment 4 weeks after its administration.
This is a preview of subscription content, log in via an institution to check access.
References
Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516–24.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–24.
Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.
Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, et al. Early prediction of response to sunitinib after imatinib failure by 18 F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. J Clin Oncol. 2009;27:439–45.
Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med. 1994;35:104–12.
Haberkorn U, Bellemann ME, Brix G, Kamencic H, Morr I, Traut U, et al. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. Eur J Nucl Med. 2001;28:418–25.
Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, et al. Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002;9:15–8.
Shreve P, Chiao PC, Humes HD, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Nucl Med. 1995;36:1595–601.
Yoshimoto M, Waki A, Yonekura Y, Sadato N, Murata T, Omata N, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol. 2001;28:117–22.
Oyama N, Okazawa H, Kusukawa N, Kaneda T, Miwa Y, Akino H, et al. 11C-Acetate PET imaging for renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2009;36:422–7.
Maleddu AM, Pantaleo MA, Castellucci P, Astorino M, Nanni C, Nannini M, et al. 11C-acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. Tumori. 2009;95:382–4.
Acknowledgments
The PET imaging was partially supported by a 21st Century COE Grant (Medical Science) and by a Grant-in Aid for Scientific Research (C) from the Japan Society for the Promotion of Science.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Oyama, N., Takahara, N., Hasegawa, Y. et al. Assessment of Therapeutic Effect of Sunitinib by 11C-Acetate PET Compared with FDG PET Imaging in a Patient with Metastatic Renal Cell Carcinoma. Nucl Med Mol Imaging 45, 217–219 (2011). https://doi.org/10.1007/s13139-011-0084-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13139-011-0084-x